芪苈强心胶囊、复方丹参滴丸对AMI患者PCI术后无复流者相关指标的影响比较
发布时间：2019-06-25 19:50
【摘要】：目的:比较芪苈强心胶囊、复方丹参滴丸对急性心肌梗死(AMI)患者经皮冠状动脉介入(PCI)术后无复流者相关指标的影响。方法:90例AMI患者PCI术后存在无复流者随机分为复方丹参滴丸组(45例)和芪苈强心胶囊组(45例)。PCI术前两组患者均嚼服1次阿司匹林咀嚼片300 mg,硫酸氢氯吡格雷片300 mg。术后,两组患者均嚼服阿司匹林咀嚼片100 mg,每日1次+辛伐他汀咀嚼片10 mg,每日1次。在此基础上,复方丹参滴丸组患者给予复方丹参滴丸10丸,口服,每日3次;芪苈强心胶囊组患者给予芪苈强心胶囊4粒,口服,每日3次。两组均连用6个月。观察两组患者治疗前后心肌梗死溶栓治疗(TIMI)血流分级、左心室射血分数(LEVF)和β_1-肾上腺素能受体抗体(β_1-AR)、β_2-AR、α_1-AR水平,出血及主要心血管事件发生情况,并记录不良反应发生情况。结果:治疗前,两组患者TIMI血流分级、LEVF、β_1-AR、β_2-AR、α_1-AR水平比较,差异均无统计学意义(P0.05)。治疗后,两组患者TIMI血流分级0~2级例数均显著低于同组治疗前,3级例数均显著高于同组治疗前;LEVF水平均显著高于同组治疗前,且芪苈强心胶囊组LEVF水平显著高于复方丹参滴丸组;β_1-AR、β_2-AR、α_1-AR水平均显著低于同组治疗前,差异均有统计学意义(P0.05)。两组患者出血发生率、主要心血管事件发生率比较,差异均无统计学意义(P0.05)。两组患者治疗期间均未见明显不良反应发生。结论:芪苈强心胶囊在改善AMI患者PCI术后无复流的效果、安全性方面与复方丹参滴丸相当,在改善心功能方面优于复方丹参滴丸。
[Abstract]:Objective: to compare the effects of Qili Qiangxin capsule and compound Danshen dropping pills on the related indexes of non-reflow patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods: 90 patients with AMI without reflow after PCI were randomly divided into compound Danshen dropping pill group (n = 45) and Qili Qiangxin capsule group (n = 45). Both groups were chewed with aspirin chewable tablet 300 mg, hydroclopidogrel sulfate 300 mg. before). PCI. The patients were randomly divided into two groups: compound salvia miltiorrhiza group (n = 45) and Qili Qiangxin capsule group (n = 45). After operation, the patients in both groups were chewed with aspirin chewing tablets once a day for 10 mg, once a day. On this basis, the patients in the compound Danshen dropping pill group were given 10 oral Danshen dropping pills, 3 times a day, and the patients in the Qili Qiangxin capsule group were given 4 Qili Qiangxin capsule, oral three times a day. Both groups were used for 6 months. The blood flow grading of (TIMI), left ventricular ejection fraction (LEVF) and 尾 _ 1-adrenergic receptor antibody (尾 _ 1-AR), 尾 _ 2 鈮，
本文编号：2505958
[Abstract]:Objective: to compare the effects of Qili Qiangxin capsule and compound Danshen dropping pills on the related indexes of non-reflow patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods: 90 patients with AMI without reflow after PCI were randomly divided into compound Danshen dropping pill group (n = 45) and Qili Qiangxin capsule group (n = 45). Both groups were chewed with aspirin chewable tablet 300 mg, hydroclopidogrel sulfate 300 mg. before). PCI. The patients were randomly divided into two groups: compound salvia miltiorrhiza group (n = 45) and Qili Qiangxin capsule group (n = 45). After operation, the patients in both groups were chewed with aspirin chewing tablets once a day for 10 mg, once a day. On this basis, the patients in the compound Danshen dropping pill group were given 10 oral Danshen dropping pills, 3 times a day, and the patients in the Qili Qiangxin capsule group were given 4 Qili Qiangxin capsule, oral three times a day. Both groups were used for 6 months. The blood flow grading of (TIMI), left ventricular ejection fraction (LEVF) and 尾 _ 1-adrenergic receptor antibody (尾 _ 1-AR), 尾 _ 2 鈮，
本文编号：2505958
本文链接：https://www.wllwen.com/yixuelunwen/xxg/2505958.html
最近更新
教材专著
